Pasithea Therapeutics financials
$0.4900+2.08%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $15.1K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | -$2.2K |
| Gross margin | — | — | — | — | −14.7% |
| Operating income | -$20.9M | -$14.2M | -$16.0M | -$13.6M | -$4.5M |
| Net income | -$20.4M | -$13.9M | -$16.0M | -$13.9M | -$2.2M |
| Net margin | — | — | — | — | −14430.5% |
| Diluted EPS | $-2.91 | $-12.69 | $-13.01 | $-11.03 | $-4.20 |
| EBITDA | -$20.2M | -$13.6M | -$15.3M | -$12.6M | -$4.5M |
| Operating cash flow | -$15.2M | -$13.9M | -$13.4M | -$13.7M | -$3.2M |
| Free cash flow | -$15.2M | -$13.9M | -$13.5M | -$13.8M | -$3.2M |
| Diluted shares | 7.0M | 1.1M | 1.2M | 1.3M | 0.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $55.2M | $6.9M | $16.3M | $33.1M | $53.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $60.2M | $16.1M | $26.1M | $45.2M | $53.3M |
| Total liabilities | $5.0M | $1.3M | $2.7M | $2.5M | $1.9M |
| Shareholders' equity | $55.2M | $14.8M | $23.4M | $42.6M | $51.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology